0000790502-15-000051.txt : 20150608
0000790502-15-000051.hdr.sgml : 20150608
20150608110950
ACCESSION NUMBER: 0000790502-15-000051
CONFORMED SUBMISSION TYPE: SC 13G/A
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20150608
DATE AS OF CHANGE: 20150608
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: CTI BIOPHARMA CORP
CENTRAL INDEX KEY: 0000891293
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911533912
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-48459
FILM NUMBER: 15917756
BUSINESS ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 2062827100
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 19960321
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: EAGLE ASSET MANAGEMENT INC
CENTRAL INDEX KEY: 0000790502
IRS NUMBER: 592385219
STATE OF INCORPORATION: FL
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: SC 13G/A
BUSINESS ADDRESS:
STREET 1: 880 CARILLON PARKWAY
CITY: ST PETERSBURG
STATE: FL
ZIP: 33716
BUSINESS PHONE: 7275732453
MAIL ADDRESS:
STREET 1: 880 CARILLON PARKWAY
CITY: ST PETERSBURG
STATE: FL
ZIP: 33716
SC 13G/A
1
CTIC1.txt
June 8, 2015
Securities and Exchange Commission
100 F Street NE
Washington, DC 20549
RE: Schedule 13G
CTI Biopharma Corp.
As of May 31, 2015
Gentlemen:
In accordance with Section 13(d)(5) of the Securities Exchange Act
of 1934, attached please find a copy of Schedule 13G for the above
named company showing a change in beneficial ownership of 5% or more
as of May 31, 2015 filed on behalf of Eagle Asset Management,Inc.
Very truly yours,
Damian Sousa
Vice President
Chief Compliance Officer
Enclosures
cc: Office of the Corporate Secretary
CTI BioPharma Corporation
3101 Western Avenue
Suite 600
Seattle WA, 98121
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1 )*
CTI BIOPHARMA CORP.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
12648L106
(CUSIP Number)
Check the following box if a fee is being paid with this statement
_____. (A fee is not required only if the filing person: (1) has
a previous statement on file reporting beneficial ownership of more
than five percent of the class of securities described in Item 1;
and (2) has filed no amendment subsequent thereto reporting beneficial
ownership of five percent or less of such class.) (See Rule 13d-7.)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
Page 1 of 5 Pages
CUSIP NO. 12648L106 13G
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Eagle Asset Management, Inc. 59-2385219
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) ______
(B) ______
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
State of Florida
NUMBER OF 5 SOLE VOTING POWER
SHARES 972,419
BENEFICIALLY 6 SHARED VOTING POWER
OWNED - - -
AS OF
May 31, 2015 7 SOLE DISPOSITIVE POWER
BY EACH 972,419
REPORTING 8 SHARED DISPOSITIVE POWER
PERSON WITH - - -
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
972,419
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_____]
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
0.54%
12 TYPE OF REPORTING PERSON*
IA
_____________________________________________________________
*SEE INSTRUCTION BEFORE FILLING OUT!
_____________________________________________________________
Page 2 of 5 Pages
Item 1(a) Name of Issuer:
CTI BIOPHARMA CORP.
Item 1(b) Address of Issuer's Principal Executing Offices:
3101 Western Avenue
Suite 600
Seattle, WA 98121
Item 2(a) Name of Person Filing:
Eagle Asset Management, Inc.
Item 2(b) Address of Principal Business Office:
880 Carillon Parkway
St. Petersburg, Florida 33716
Item 2(c) Citizenship:
Florida
Item 2(d) Title of Class of Securities:
Common Stock
Item 2(e) CUSIP Number:
12648L106
Item 3 Type of Reporting Person:
(e) Investment Adviser registered under Section 203 of the Investment
Advisors Act of 1940
Page 3 of 5 Pages
Item 4 Ownership as of May 31, 2015
(a) Amount Beneficially Owned:
972,419 shares of common stock beneficially owned including:
No. of Shares
Eagle Asset Management, Inc. 972,419
(b) Percent of Class: 0.54%
(c) Deemed Voting Power and Disposition Power:
(i) (ii) (iii) (iv)
Deemed Deemed
Deemed Deemed to have to have
to have to have Sole Power Shared Power
Sole Power Shared Power to Dispose to Dispose
to Vote or to Vote or or to or to
to Direct to Direct Direct the Direct the
to Vote to Vote Disposition Disposition
Eagle Asset 972,419 ---- 972,419 ----
Management, Inc.
Item 5 Ownership of Five Percent or Less of a Class:
If this statement is being filed to report the fact that
as of the date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check the
following.
(__X__)
Item 6 Ownership of More than Five Percent on Behalf of Another Person:
N/A
Item 7 Identification and Classification of the Subsidiary which Acquired
the Security Being Reported on by the Parent Holding Company:
N/A
Page 4 of 5 Pages
Item 8 Identification and Classification of Members of the Group: N/A
Item 9 Notice of Dissolution of Group: N/A
Item 10 Certification:
By signing below I certify that to the best of my
knowledge and belief, the securities referred to above were acquired
in the ordinary course of business and were not acquired for purpose of
and do not have the effect of changing or influencing the control of
the issuer of such securities and were not acquired in connection with
or as a participant in any transaction having such purposes or effect.
Signature
After reasonable inquiry and to the best of my knowledge
and belief, I certify that the information set forth in this statement is
true, complete and correct.
Date: June 8, 2015 EAGLE ASSET MANAGEMENT, INC.
/s/ Damian Sousa
_________________________________
Damian Sousa
Vice President
Chief Compliance Officer
Page 5 of 5 Pages